Trial · NCT00465985
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) | ACZ885 | 0 | percent of participants | ||
| Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) | Placebo | 81.3 | percent of participants | ||
| Number of Participants With Treatment Response in Part I (After 8 Weeks) | ACZ885 | Complete response | 31 | 25.200 | Participants |
| Number of Participants With Treatment Response in Part I (After 8 Weeks) | ACZ885 | Partial response | 2 | Participants | |
| Number of Participants With Treatment Response in Part I (After 8 Weeks) | ACZ885 | Disease flare | 1 | Participants | |
| Number of Participants With Treatment Response in Part I (After 8 Weeks) | ACZ885 | Non-responder (protocol violation) | 1 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | ACZ885 | Absent | 8 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | Placebo | Absent | 0 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | ACZ885 | Minimal | 7 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | Placebo | Minimal | 4 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | ACZ885 | Mild | 0 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | Placebo | Mild | 8 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | ACZ885 | Moderate | 0 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | Placebo | Moderate | 4 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | ACZ885 | Severe | 0 | Participants | |
| Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part) | Placebo | Severe | 0 | Participants | |
| Change in Inflammation Markers at the End of Part II (C-reactive Protein and/or Serum Amyloid A) (After 24 Weeks of the Double-blind Part) From Week 8. | ACZ885 | C reactive protein (CRP (mg/L)) | 1.10 | Standard Deviation 3.086 | mg/L |
| Change in Inflammation Markers at the End of Part II (C-reactive Protein and/or Serum Amyloid A) (After 24 Weeks of the Double-blind Part) From Week 8. | Placebo | C reactive protein (CRP (mg/L)) | 19.93 | Standard Deviation 24.175 | mg/L |
| Change in Inflammation Markers at the End of Part II (C-reactive Protein and/or Serum Amyloid A) (After 24 Weeks of the Double-blind Part) From Week 8. | ACZ885 | Serum amyloid A (SAA (mg/L)) | 2.27 | Standard Deviation 8.604 | mg/L |
| Change in Inflammation Markers at the End of Part II (C-reactive Protein and/or Serum Amyloid A) (After 24 Weeks of the Double-blind Part) From Week 8. | Placebo | Serum amyloid A (SAA (mg/L)) | 71.09 | Standard Deviation 136.637 | mg/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00465985/results